Chronic Kidney Disease

The Kidney Disease: Improving Global Outcomes guidelines can provide pharmacists with approaches to minimizing chronic kidney disease progression and complications.

The observational study shows a positive correlation between smoking and chronic kidney disease (CKD) whereas the analyses imply smoking-related covariates may be a factor.

Early diagnosis of chronic kidney disease (CKD) can help optimize treatment and manage the disease to prevent further decline.

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

Zaltenibart could be an effective treatment option for C3 glomerulopathy as the most proximal inhibitor of the alternative pathway.

The results validate the protective benefits of the sodium–glucose cotransporter-2 inhibitors on renal function for those with type 2 diabetes.

Although disease screening reached high-risk patients, uptake was low, necessitating additional incentive to participate in voluntary testing.

Full traditional approval follows accelerated approval of the medication last year.

Pegcetacoplan is a targeted C3 therapy that is intended to regulate excessive activation of the complement cascade.

The indication is for the reduction of proteinuria in adult patients who have primary immunoglobulin A nephropathy and are at risk of disease progression.

Emerging treatments, collaboration between health care providers, and new policy proposals have led to a positive outlook for the future of nonalcoholic steatohepatitis (NASH) and its treatment.

More cost effectiveness data is crucial in advocating for better insurance coverage in the United States.

Benefits of semaglutide on cardiovascular outcomes, such as death, non-fatal myocardial infarction, and non-fatal stoke, were also presented at the session at American Diabetes Association 84th Scientific Sessions.

Presenters at the American Diabetes Association 84th Scientific Sessions analyzed potential developments in treatment for patients with diabetes and diabetic kidney disease.

The role of semaglutide as a glucagon-like peptide-1 (GLP-1) receptor antagonist could offer further treatment options to improve patient outcomes.

Iptocopan demonstrated superiority when treating patients with immunoglobulin A nephropathy and is the first drug to specifically target the alternative complement pathway.

IMPACT CKD, a modeling analysis created by AstraZeneca, includes data about chronic kidney disease across 8 countries, including the United States.

The abstracts will be presented at the American College of Cardiology Conference from April 6 to April 8, 2024, in Atlanta, Georgia.

The results further confirm earlier findings from the EMPA-KIDNEY trial.

The ODD comes after AP303 presented meaningful improvements in renal survival in an ADPKD and the completion of the first study that evaluated healthy human participants.

Vadadustat (Vafseo; Akebia Therapeutics Inc) is indicated for individuals with chronic kidney disease who have been receiving dialysis for at least 3 months.

Previously, felzartamab received orphan drug designation and breakthrough therapy designation for the treatment of primary membranous nephropathy.

In the study, investigators found superior kidney outcomes with injectable semaglutide (Ozempic) for individuals with type 2 diabetes and chronic kidney disease.

This agent can prevent the depletion of heparan sulphate in the endothelial glycocalyx layer of endothelial cells, ultimately protecting against vision loss and renal failure caused by diabetes.

According to the FDA review, patients with CKD receiving denosumab for osteoporosis who are on dialysis or have CKD-MBD are at the highest risk of severe hypocalcemia.

Increased waist circumference and high blood pressure can disrupt circadian rhythm, which can increase risk of progression to poor renal outcomes.

The update includes a recommended triple therapy with belimumab as a first line treatment for class III or IV lupus nephritis following the approvals of belimumab and voclosporin.

Tarpeyo is now the first fully FDA-approved treatment for primary immunoglobulin A nephropathy, based on measures of kidney function.

These drugs have interesting mechanisms, unique use, or may support expanded indications in the future.

Axitinib, cabozantinib, and lenvatinib are first-line treatment options.